Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion

BMC Cardiovascular Disorders

Volumn 2, Issue , 2002, Pages

  Bertuglia, Silva ^a   Giusti, Andrea ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; SODIUM CHLORIDE; TISSUE PLASMINOGEN ACTIVATOR; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; ATTENUATION; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; CAPILLARY; CHEEK POUCH; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE; FLOW RATE; FLUORESCENCE MICROSCOPY; HAMSTER; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; MALE; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; TISSUE PERFUSION; ANIMAL; CHEEK; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; LEUKOCYTE; MICROCIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE AGGREGATION; VENULE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTERIOLES; CAPILLARIES; CHEEK; CRICETINAE; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; IMMUNOGLOBULIN FAB FRAGMENTS; LEUKOCYTES; MICROCIRCULATION; PEPTIDES; PLASMINOGEN ACTIVATORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REPERFUSION INJURY; VENULES;

EID: 0642281272     PISSN: 14712261     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2261-2-10     Document Type: Article

References (31)

1. Golino , Maroko PR, Carew TE: Efficacy of platelet depletion in counteracting the detrimental effect of acute hypercolesterolemia on infarct size and the no-reflow phenomenon in rabbits undergoing coronary artery occlusion-reperfusion. Circulation 1987, 76:173
2. Massberg S, Enders G, de Melo-Matos FC, LID Tomic, Leiderer R, Eisenmenger S, Messmer K, Krombach F: Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia reperfusion in vivo. Blood 1999, 94:3829
3. Salter W, Krieglstein CF, Issekutz AC, Granger DN: Platelets modulate ischemia reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol 2001, 281:G1432
4. Bertuglia S, Giusti A, Fedele S, Picano E: Glucose-insulin-potassium treatment in combination with dipyridamole inhibits ischemia-reperfusion-induced damage. Diabetologia 2001, 44:2165-2170
5. Cook NS, Kottirsch G, Zerwes HG: Platelet glycoproteins IIb/IIIa antagonists. Drugs of the future 1994, 19:135-159
6. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIa receptor in high-risk coronary angioplastly: The EPIC investigation. N Engl J Med 1994, 330:956
7. Schulman SP, Goldschmidt-Clennont PJ, Topol EJ: Effects of Integrilin a platelet glycoprotein IIb/IIa receptor antagonist in unstable angina, a multicenter trial. Circulation 1996, 94:2083-89
8. 3 Integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001, 104:582-587
9. Foster RH, Wiseman LR: Abciximab. An update review of its use in ischaemic heart disease. Drugs 1998, 56(4):629-665
10. Rote WE, Werns SW, Davis JH, Feigen LP, Kilgore KS, Lucchesi BR: Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. Cardiovasc Res 1993, 27:500-507
11. Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalesot G, Miller DP, Ferguson JJ, Willerson JT, Topol EJ: Long-term mortality benefit with Abciximab in patients undergoing percutaneous coronary intervention. JACC 2001, 37:2059-65
12. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topoll EJ: Abiciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001, 104:163-167
13. Brener SJ, Zeymer U, Adjey J, Vrobel TR, Ellis SG, Neuhaus KL, Juran N, Ivanc TB, Ohman EM, Strony J, Kitt M, Topol EJ: Eptifibatide and low-dose tissue plasminogen activactor in acute myocardial infarction. JACC 2002, 39:377-86
14. 3 Integrilin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001, 104:582-587
15. Goto S, Sakay H, Goto M, Ono M, Ikeda Y, Handa S, Ruggeri ZM: Enhanced shear rate-induced platelet aggregation in acute myocardial infarction. Circulation 1999, 99:608-11
16. Andre P, Denis CV, Ware J, Saffaripout S, Hynes R, Ruggeri M, Wagner DD: Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000, 96:3322-30
17. Binnema DJ, Dooijewaard G, Turion NC: An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. Thromb. Haem 1991, 65:144-148
18. Watkins SP, de Lemos JA: Antiplatelet therapy in AMI: Combining GP IIb/IIIa inhibition with reduced-dose fibrinolytic therapy. Curr Interv Cardiol Rep 2001, 3:235-43
19. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis S, Cohen G, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KM, Califf RM, Krucoff MW, Topol EJ: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACTAMI Investigators. Circulation 1997, 95:793-801
20. Bertuglia S, Colantuoni A: Protective effects of leukopenia and tissue plasminogen activator in microvascular ischemiareperfusion injury Am J Physiol 2000, 278:H755-H761
21. Baldassarre JJ, Henderson PA, Burns D, Fisher JY: Translocation of protein kinase C isozymes in thrombin stimulated human platelet. Correlation with 1,2 dyacylglycerol levels. J Biol Chem 1992, 267:15585-92
22. Rubanyi GM, V PM: Oxygen derived free radicals, endothelium and responsiveness of vascular smooth muscle. Am J Physiol 1986, 250:H815-21
23. Davenpeck KL, Gauthier TW, Lefer AM: Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastrenter 1994, 107:1050-8
24. Folts JD, Gallagher K, Rowe GG: Blood flow reductions canine coronary arteries: vasospam or platelet aggregation? Circulation 1982, 65:248-55
25. Simon DU, Xu H, Ortlepp P, Rogers C, Rao NK: 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leukocyte integrin Mac-I and blocks adhjesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997, 17:528-35
26. Kurose I, Anderson DC, MiYasaka M, Tamatani T, Paulson JC, Todd RF, Rusche JR, Granger DN: Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circul Res 1994, 74:336-42
27. Haj MA, Neilly IJ, Robbie LA, Adey GD, Bennett B B: Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leucopenia. Br J Haematol 1995, 90:541-7
28. Campbell B, Chuhran CM, Lefer DJ, Lefer AM: Cardioprotective effects of Abciximab (ReoPro) in an isolated perfused rat heart model of ischemia and reperfusion. Methods Find Exp Clin Pharmacol 1999, 21(8):529-534
29. Riesenberg K, Sclaeffer K, Katz A, Levy R: Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents. Br Heart J 1998, 73:14-19
30. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI: Abciximab suppresses the rise in levels of circulatory inflammatory markers after percutaneous coronary revascularization. Circulation 2001, 104:163-167
31. Yamada S, Yamada R, Ishii A A, Ashikawa K, Kawamitsu H, Fujita K: Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction. J Cardiol 1996, 27(4):171-8